1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Chong Kun Dang Pharmaceutical Corp.

Chong Kun Dang Pharmaceutical Corp.

185750.KS
Chong Kun Dang Pharmaceutical Corp.KR flagKorea Exchange
70,200.00
KRW
+400.00
- -
924.96BMarket Cap
Chong Kun Dang Pharmaceutical Corp.
185750.KS
(Korea Exchange)

Recent

price

70,200.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
6,216.71
39,161.19
42,632.14
59,879.37
60,616.73
69,202.82
78,131.27
94,385.26
98,048.45
105,291.82
113,788.74
119,760.99
128,433.85
131,983.67
Revenue per Share
318.11
2,530.03
-487.32
2,946.96
3,688.1
3,068.44
3,900.39
6,637.56
3,117.59
5,726.98
14,485.71
8,234
5,882
5,960.71
Basic EPS, GAAP
564.71
3,113.89
-2,043.57
1,320.44
4,136.61
1,301.78
3,795.22
4,889.91
-2,841.75
1,037.8
16,996.28
-136.88
-8,482.29
-12,083.09
Free Cash Flow per Basic Share
- -
203.04
541.31
406.08
580.1
612.5
639.84
672
788.75
795.08
791.25
1,006.37
1,049.08
- -
Dividend per Share
1,943.09
4,180.87
3,098.04
5,931.29
8,879.98
11,850.73
15,241.67
21,688.11
24,131.32
28,746.28
41,470.93
53,173.69
58,749.22
59,303.48
Book Value per Share
20,186.75
22,697.57
21,493.84
24,426.61
26,660.49
30,072
33,228.93
38,576.84
39,772.57
42,045.83
52,014.42
61,957.94
68,212.18
68,915.65
Tangible Book Value per Share
14
14
14
14
15
14
14
14
14
14
15
13
13
13
Basic Weighted Avg Shares
86,318
544,130
592,493
831,986
884,363
956,219
1,079,338
1,303,006
1,343,559
1,488,345
1,669,404
1,586,431
1,692,404
1,739,214
Sales/Revenue/Turnover
8.73
9.91
7.21
7.36
8.79
7.92
6.91
9.51
7.05
7.38
14.77
6.27
4.76
4.73
Operating Margin (%)
3,280
20,548
22,677
23,934
21,985
21,218
23,052
23,786
27,482
33,598
37,030
39,772
44,798
45,174
Depreciation Expense
4,417
35,154
-6,773
40,946
53,807
42,399
53,882
91,633
42,720
80,953
212,521
109,073
77,509
78,547
Net Income, GAAP
26.47
27.49
144.74
27.9
27.98
38.98
26.24
25.8
47.44
17.69
11.59
- -
4.69
3.93
Effective Tax Rate (%)
5.12
6.46
-1.14
4.92
6.08
4.43
4.99
7.03
3.18
5.44
12.73
6.88
4.58
4.52
Profit Margin (%)
124,450
137,118
136,923
127,315
142,857
185,822
194,066
279,493
346,917
339,402
435,106
593,594
575,695
522,641
Working Capital
61,000
43,967
70,600
40,000
21,358
45,892
25,845
57,509
134,962
111,293
34,997
118,681
201,892
201,778
LT Debt
298,124
331,448
314,561
354,250
403,295
430,900
474,953
551,593
565,810
621,289
815,635
896,378
1,006,356
1,028,780
Total Equity
- -
8.83
-4.17
9.31
10.91
8.51
9.42
13.86
6.48
10.61
22.1
- -
6.15
6.3
Return on Invested Capital (%)
- -
23.37
-4.98
23.47
25.61
17.76
19.02
25
9.01
14.49
29.9
- -
8.2
8.35
Return on Capital (%)
- -
82.65
-13.39
65.27
50.77
28.91
28.79
35.94
13.56
21.97
41.89
16.62
10.48
10.57
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
165,778
165,866
166,227
LT Borrowings
44,270
195,196
195,377
LT Finance Leases
1,320
6,697
6,401
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
1,081,951
1,092,494
1,174,115

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
871,166
1,091,819
1,045,164
Cash, Cash Equivalents & STI
136,565
346,503
285,226
Accounts Receivable, Net
277,092
265,843
259,315
Inventories
401,991
428,649
444,339
Total Current Liabilities
461,254
516,124
522,523
Payables & Accruals
- -
- -
- -
ST Debt
165,778
165,866
166,227
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.55%
13.17%
12.27%
Free Cash Flow
748.24%
1,453.6%
6,064.32%
Net Income, GAAP
-47.62%
24.2%
-28.94%
Sales/Revenue/Turnover
11.62%
5.55%
6.68%
Total Cash Common Dividend
- -
8.46%
3.7%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
361,502
396,802
412,762
415,364
1,586,431
2025
400,956
434,849
429,819
426,780
1,692,404
2026
447,766
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,829.52
3,824.76
1,565.71
- -
8,234
2025
894
1,446.87
1,525.69
- -
5,882
2026
973.02
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1,006.37
2025
- -
- -
- -
- -
1,049.08
2026
- -
- -
- -
- -
- -
Similar Companies
RBC Life Sciences, Inc. (RBCL)
Burzynski Research Institute, Inc. (BZYR)
China Health Group Inc. (8225.HK)
Pilulka Lékárny a.s. (PINK.PR)
Inhibitor Therapeutics, Inc. (CBTE)
Jenkem Technology Co., Ltd. (688356.SS)
Business
Chong Kun Dang Pharmaceutical Corp. Chong Kun Dang Pharmaceutical Corp. (185750.KS) manufactures, markets, and sells prescription and over-the-counter pharmaceuticals primarily in South Korea and internationally; its core products include prescription drugs such as the anticancer agent Camptobell (belotecan), antidiabetic Duvie (lobeglitazone), antihypertensives Dilatrend (carvedilol) and Telminuvo, anti-hyperlipidemics Lipilou, and immunosuppressant Tacrbell, alongside OTC remedies like headache treatment Penzal, antithelmintic Zelcom, digestive aid Sok-chung, women's health products Prefemine and Simidona, supplements including prebiotics Prelacto and omega-3 vitamins, healthy beverages such as Ja-Whang and red-ginseng drinks, and consumer health items like insecticides Jjong aerosol. The company, founded on May 7, 1941, and spun off on November 5, 2013, is headquartered at 8, Chungjeong-ro, Seodaemun-gu, Seoul, South Korea, and operates manufacturing facilities in CheonAn for global exports to regions including Japan, China, Southeast Asia, MENA, Africa, and Europe, supported by a Vietnam representative office since 2012 and an Indonesian joint venture PT CKD OTTO Pharmaceuticals established in 2015 with a halal-certified anticancer factory added in 2019. Chong Kun Dang Pharmaceutical Corp. maintains partnerships with multinational firms including Bayer, Roche, Pfizer, MSD, Amgen, Novartis, and Synaffix for in-licensed products like Avelox, Januvia family, Prolia, and ADC technologies; recent developments encompass a November 2023 $1.305 billion technology export deal with Novartis for HDAC6 inhibitor CKD-510 targeting autoimmune, neurological, and oncology indications, a 2.2 trillion won investment announced in October 2025 for a biopharmaceutical R&D complex in Siheung City, establishment of U.S. subsidiary CKD USA in Boston in 2024 as a global R&D hub, milestone payments from Novartis in May 2025 following Phase 2 trial submission for CKD-510, and advancements in pipelines like anticancer CKD-516, CKD-581, CGT/ADC therapies CKD-702 and CKD-703, and HDAC6-selective inhibitors.

Company News

APIChatGPT

  • businesswire.com

    Can-Fite Granted Patent Allowance for its NASH Drug Namodenoson in South Korea; Results of its NASH Phase II Study are Expected this Quarter